Collaborations
Teaming up to make a difference
We work with collaborators and funders to advance our ultimate goal of developing life-saving therapeutics.
Variant Bio has launched a multi-year research collaboration with Novo Nordisk to identify and validate novel targets with strong genetic evidence for the treatment of metabolic disease. The project leverages Variant Bio’s innovative VB-Inference analysis platform and expertise partnering with global populations as well as Novo Nordisk’s vast experience in metabolic disease drug discovery.
Read the New York Times article - January 7, 2025
Read the Press Release - January 7, 2025
Variant Bio has entered a strategic partnership with Evotec to elucidate a key fibrotic pathway with strong genetic support identified by Variant Bio and progress the program toward the selection of a clinical development candidate(s). The collaboration leverages Variant Bio’s cutting-edge genomic discovery capabilities and VB-Inference platform as well as Evotec’s extensive expertise in antifibrotic drug discovery.
Variant Bio has received support from the Bill & Melinda Gates Foundation for a two-year project to map global variation in immune-related genes, such as HLA alleles, which influence vaccine efficacy and disease susceptibility. The findings, crucial for advancing vaccines like those for HIV and tuberculosis, will be made publicly accessible to promote public health initiatives worldwide.